The fully linked HTML version of this article has now been published.
JCS ePress
online publication date 6 Jun 2006
doi: 10.1242/jcs.03011
Research Article
Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species
Bahar Cat,
Dominik Stuhlmann,
Holger Steinbrenner,
Lirija Alili,
Olaf Holtkötter,
Helmut Sies,
and
Peter Brenneisen*
* Author for correspondence (e-mail: PeterBrenneisen{at}web.de)
Myofibroblasts, pivotal for tumor progression, populate the microecosystem of reactive stroma. Using an in vitro tumor-stroma model of skin carcinogenesis, we report here that tumor-cell-derived transforming growth factor
1 (TGF
1) initiates reactive oxygen species-dependent expression of
-smooth muscle actin, a biomarker for myofibroblastic cells belonging to a group of late-responsive genes. Moreover, protein kinase C (PKC) is involved in lipid hydroperoxide-triggered molecular events underlying transdifferentiation of fibroblasts to myofibroblasts (mesenchymal-mesenchymal transition, MMT). In contrast to fibroblasts, myofibroblasts secrete large amounts of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6), resulting in a significant increase in the invasive capacity of tumor cells. The thiol N-acetyl-L-cysteine, the micronutrient selenite as well as selenoprotein P and the lipid peroxidation inhibitors
-tocopherol and butylated hydroxytoluene significantly lower both the number of TGF
1-initiated myofibroblasts and the secretion of HGF, VEGF and IL-6, correlating with a diminished invasive capacity of tumor cells. This novel concept of stromal therapy, namely the protection of stromal cells against the dominating influence of tumor cells in tumor-stroma interaction by antioxidants and micronutrients, may form the basis for prevention of MMT in strategies for chemoprevention of tumor invasion.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. K. Witkiewicz, A. Dasgupta, F. Sotgia, I. Mercier, R. G. Pestell, M. Sabel, C. G. Kleer, J. R. Brody, and M. P. Lisanti
An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers
Am. J. Pathol.,
June 1, 2009;
174(6):
2023 - 2034.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Sotgia, F. Del Galdo, M. C. Casimiro, G. Bonuccelli, I. Mercier, D. Whitaker-Menezes, K. M. Daumer, J. Zhou, C. Wang, S. Katiyar, et al.
Caveolin-1-/- Null Mammary Stromal Fibroblasts Share Characteristics with Human Breast Cancer-Associated Fibroblasts
Am. J. Pathol.,
March 1, 2009;
174(3):
746 - 761.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Rocks, G. Paulissen, F. Quesada-Calvo, C. Munaut, M.-L. A. Gonzalez, M. Gueders, J. Hacha, C. Gilles, J.-M. Foidart, A. Noel, et al.
ADAMTS-1 Metalloproteinase Promotes Tumor Development through the Induction of a Stromal Reaction In vivo
Cancer Res.,
November 15, 2008;
68(22):
9541 - 9550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Werth, D. Stuhlmann, B. Cat, H. Steinbrenner, L. Alili, H. Sies, and P. Brenneisen
Stromal resistance of fibroblasts against oxidative damage: involvement of tumor cell-secreted platelet-derived growth factor (PDGF) and phosphoinositide 3-kinase (PI3K) activation
Carcinogenesis,
February 1, 2008;
29(2):
404 - 410.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Sasser, N. J. Sullivan, A. W. Studebaker, L. F. Hendey, A. E. Axel, and B. M. Hall
Interleukin-6 is a potent growth factor for ER-{alpha}-positive human breast cancer
FASEB J,
November 1, 2007;
21(13):
3763 - 3770.
[Abstract]
[Full Text]
[PDF]
|
 |
|
© The Company of Biologists Ltd 2006